

possess antiviral activity. Two active antiflogistics are not virus inhibitors. It may be supposed antiviral activity of antiflogistics in part is due to an influence at the virus penetration. It is affirmed indirectly by nonspecific antiviral activity of compounds mentioned above. 1-Methyl-4-(N-benzylcarbamido)-pyridinium iodide (amizon) is effective in treatment of herpes, influenza, and measles. Three amizon analogs are active against several viruses as well.

doi:10.1016/j.antiviral.2009.02.127

123

Synthesis, Antiviral Activity, and Cytotoxicity of Some Novel 2-Phenyl-3-disubstituted Quinazolin-4(3H)-ones

Periyasamy Selvam^{1,*}, Julie M. Breitenbach², Katherine Z. Borysko², John C. Drach²

¹ Amrita School of Pharmacy, AIMS Campus, Elamakkara, Kochi 682026, India; ² School of Dentistry and College of Pharmacy, University of Michigan, Ann Arbor, USA

Quinazoline is the versatile lead molecule for designing potential antiviral agents. Its derivatives have been reported to possess broad spectrum antiviral activity. In the current study, 2-phenyl-benzoxazin-4-ones was condensed with selected primary amines to form the corresponding 2,3-disubstituted quinazolin-4(3H)-ones. Their chemical structure was elucidated by means of spectral (FT-IR, ¹H-NMR, MS) and elemental analysis. Antiviral activity of the compounds was evaluated in plaque assays using herpes simplex virus type 1 (HSV-1), human cytomegalovirus (HCMV), vaccinia virus (VV) and cowpox virus (CPV). Cytotoxicity was determined in stationary human foreskin fibroblasts (HFF) and logarithmically growing KB cells. Compounds AA-1, AA-2, DBR-2, and MBR-2 had modest activity (IC₅₀ = 20–60 μM) against VV and/or CPV, similar to cidofovir. Little cytotoxicity was observed at concentrations up to 100 μM except for MBR-2. It was cytotoxic to both HFF and KB cells at 30–40 μM thereby implying that antiviral activity was a manifestation of cytotoxicity. Similar conclusions were reached for activity of MBR-2 against HSV-1 and HCMV. The other seven compounds had modest activity against HSV-1 (25–40 μM) but with some cytotoxicity noted at 100 μM. In contrast, in an experiment using a low multiplicity of infection with HSV-1, DBR-1 and MBR-1 were active in a low micromolar range suggesting the possibility of specific antiviral activity.

Acknowledgement: Supported funds from the University of Michigan.

doi:10.1016/j.antiviral.2009.02.128

124

Expression of Infectious Bursal Disease Virus (IBDV) Polyprotein and VP4 Protease

Phillia Vukea*, Alain Boulange, Theresa Coetzer

University of Kwa-Zulu-Natal, Pietermaritzburg, South Africa

Infectious bursal disease virus consists of a bisegmented double-stranded RNA and infects the B-cells in the bursa of Fabricius of young chickens. It causes Gumboro disease, that is of considerable importance in the poultry industry. Although vaccines are available, their use is compromised by maternally derived antibodies and the emergence of very virulent strains. A promising approach is to develop anti-viral compounds that target the virus-encoded VP4 protease, which autocatalytically cleaves a 110 kDa viral polyprotein (NH₂-pVP₂-VP₄-VP₃-COOH) into pVP₂, VP₄ and VP₃. VP₂ and VP₃ are necessary for the appropriate assembly of the

infectious viral particles. It was initially suggested that VP₄ cleaves between Arg⁴⁵⁸-Arg⁴⁵⁹ and Lys⁷²²-Arg⁷²³ but site-directed mutagenesis later identified Ala⁵¹²-Ala⁵¹³ and Ala⁷⁵⁵-Ala⁷⁵⁶ as the cleavage sites and VP₄ (Ala⁵¹³-Ala⁷⁵⁵) as the mature protease. We propose that this VP₄ form is a product of the autocatalytic activity of the integral VP₄ and that it is not the mature protease. The aim of the study was to determine the sequence required for the autocatalytic activity of VP₄ and hence the sequence of the mature VP₄. Thus constructs for the expression of full-length (Met¹-Glu¹⁰¹²), truncated (Ile²²⁷-Trp⁸⁹¹) polypeptide and three forms of VP₄ with an alternative N- or C-terminus, namely VP₄-RA (Arg⁴⁵⁹-Ala⁷⁵²), VP₄-RK (Arg⁴⁵⁹-Lys⁷²²) and VP₄-AA (Ala⁵¹³-Ala⁷⁵⁵) were prepared. We also prepared anti-peptide antibodies against VP₄-RK and VP₄-AA. We report here on the expression of these various constructs in pGEX-4T-1 and pET 32a and their detection with anti-peptide antibodies towards elucidation of the sequence of the mature VP₄.

doi:10.1016/j.antiviral.2009.02.129

125

Synthesis and SAR of 9-Arylpurines as Novel Inhibitors of Enterovirus Replication

Leire Aguado^{1,*}, Hendrik Jan Thibaut², María-José Camarasa¹, Johan Neyts², María-Jesús Pérez-Pérez¹

¹ Instituto de Química Médica (CSIC), 28006 Madrid, Spain; ² Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

Enteroviruses cause often mild and self-limiting infections, but may also be involved in more serious conditions, which can be life-threatening, such as pancreatitis, meningitis, encephalitis or myocarditis. There are no drugs approved for the treatment of enterovirus infections (De Palma et al., 2008). Here we report on a novel class of enterovirus inhibitors that structurally can be described as 9-arylpurines. Interestingly, scarce examples of such kind of chemical structures are reported in the literature. Two synthetic strategies were used to obtain these compounds: (i) the coupling reaction between arylboronic acids and purines catalyzed by copper salts and (ii) a two-step classical protocol based on the reaction of chloropyrimidines with anilines followed by cyclization. For this second approach, we have set up a new microwave-assisted procedure that has significantly reduced the reaction time, therefore allowing the synthesis of a considerable number of compounds in a short period of time (Aguado et al., submitted for publication). The most selective compounds in this series inhibited viral (Coxsackie B Virus 3) replication with EC₅₀ values in the range 4–8 μM, and EC₉₀ values around 7–10 μM. CC₅₀ values were >250 μM. The most potent compounds in this series were shown to inhibit a selection of enterovirus but lacked activity against polio and rhinoviruses replication. This family of compounds is characterized by its simplicity in structure, synthetic accessibility and selective inhibitory activity against various enteroviruses replication.

References

- De Palma, A.M., Vliegen, I., DeClercq, E., Neyts, 2008. J. Med. Res. Rev. 28, 823–884.
- Aguado, L., Camarasa, M.J., Pérez-Pérez, M.J., J. Comb. Chem., submitted for publication.

doi:10.1016/j.antiviral.2009.02.130